Multifunctional fibrous wound dressings for refractory wound healing

Refractory wounds have always been an important issue to healthcare systems, whose healing process is always delayed by multiple factors, including bacterial infections, chronic inflammation, and excessive exudates, etc. Employing multifunctional wound dressings is recognized as an effective strategy to deal with refractory wounds, which has yielded promising outcomes in recent years. Among these advanced wound dressings, fibrous dressings have gained growing attention due to their unique merits. Such wound dressings have demonstrated great potential in delivering theranostic agents, such as antibacterial agents, anti-inflammatory drugs, growth factors, and diagnostic probes, etc., for the purposes of accelerating wound healing. This paper reviews the development of multifunctional fibrous dressings and their applications in treating refractory wounds. The construction approaches of novel fibrous dressing with capabilities of antibacterial, anti-inflammation, exudate management and diagnosis were also introduced. Furthermore, the existing problems and challenges are also discussed briefly.     

Investigation of mononuclear,dinuclear, and trinuclear transition metal (II) complexes derived from an asymmetric Salamo‐based ligand possessing three different coordination modes

A new asymmetric Salamo‐based ligand H₂L was synthesized using 3‐tert‐butyl‐salicylaldehyde and 6‐methoxy‐2‐[O‐(1‐ethyloxyamide)]‐oxime‐1‐phenol. By adjusting the ratio of the ligand H₂L and Cu (II), Co (II), and Ni (II) ions, mononuclear, dinuclear, and trinuclear transition metal (II) complexes, [Cu(L)], [{Co(L)}₂], and [{Ni(L)(CH₃COO)(CH₃CH₂OH)}₂Ni] with the ligand H₂L possessing completely different coordination modes were obtained, respectively. The optical spectra of ligand H₂L and its Cu (II), Co (II) and Ni (II) complexes were investigated. The Cu (II) complex is a mononuclear structure, and the Cu (II) atom is tetracoordinated to form a planar quadrilateral structure. The Co (II) complex is dinuclear, and the two Co (II) atoms are pentacoordinated and have coordination geometries of distorted triangular bipyramid. The Ni (II) complex is a trinuclear structure, and the terminal and central Ni (II) atoms are all hexacoordinated, forming distorted octahedral geometries. Furthermore, optical properties including UV–Vis, IR, and fluorescence of the Cu (II), Co (II), and Ni (II) complexes were investigated. Finally, the antibacterial activities of the Cu (II), Co (II), and Ni (II) complexes were explored. According to the experimental results, the inhibitory effect was found to be enhanced with increasing concentrations of the Cu (II), Co (II), and Ni (II) complexes.     

Antibiotics produced at the G. F. Gauze Scientific-Research Institute of New Antibiotics,Russian Academy of Medical Sciences (marking the Fiftieth Anniversary of the Institute). (Review)

The major achievements of the G. F. Gauze Scientific-Research Institute of New Antibiotics, Russian Academy of Medical Sciences, over the last 50 years are reviewed. The structures of antibiotics and related compounds discovered at the Institute and important for medical practise and/or of theoretical interest as new compounds with high biological activity are described.Dedicated to the memory of Director of the G. F. Gauze Scientific-Research Institute of New Antibiotics, Russian Academy of Medical Sciences, and Corresponding Member of the Russian Academy of Medical Sciences Prof. Yu. V. Dudnik (1938–2003).Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 11, pp. 1603–1618, November, 2004.     

Synthesis and studies of antibacterial activity of pongaglabol

Pongaglabol [8-hydroxy-5-phenyl-furo[2,3-h]benzo(b)pyran-7-one] was synthesized and tested for antibacterial effects againstShigella dysenteriae, Salmonella typhi, Streptococcus β-haemolyticus andStaphylococcus aureus. The synthesized compounds were characterized using UV, IR and¹H NMR spectral data     

2-苯甲酰基-N-芳基氨基脲的合成及抑菌活性

以N-取代三氯乙酰胺在碱催化下与苯甲酰肼反应,合成了8种2-苯甲酰基-N-芳基氨基脲3a～3h,其结构经元素分析、IR和1H NMR所表征;初步生物活性测定表明,部分化合物对大肠杆菌、枯草杆菌和金黄色葡萄球菌具有一定的抑菌活性.     

取代二噁二唑硫醚及砜衍生物合成及抗菌活性

取代二噁二唑硫醚及砜衍生物合成及抗菌活性     

2''''-(1-萘亚甲基)-2-羟基苯甲酰腙的合成、晶体结构及抑菌活性

某些席夫碱化合物具有抗肿瘤、抗菌等生物活性，在生化反应中起到转氨基作用，碳氨双键是该类化合物具有抗菌活性的效应基团。而含-CONHN=CH-基团的酰腙类化合物具有特殊的生物活性和强配位能力，在农药、医药和分析试剂等方面一直是人们广泛研究的对象，某些该类化合物在治疗一些疾病和抑菌方面已有广泛的应用。为了进一步探索高效抗菌药物，本研究组在从事席夫碱及腙类化合物的合成、生物活性的测定等工作中合成了标题化合物；并测定了标题化合物对枯草芽孢杆菌、肺炎克氏菌、铜绿脓杆菌、大肠杆菌和金黄色葡萄球菌的抑菌活性。     

纳米稀土谷氨酸咪唑三元配合物的合成、表征及抗菌活性研究

合成了6种新型纳米稀土三元配合物。通过元素分析、摩尔电导、红外光谱、紫外光谱、氢谱、碳谱、热重-差热等表征,确定了该类配合物的化学组成为：RE（Glu）3ImCl3·3H2O（RE=La^3＋,Nd^3＋,Er^3＋,Eu^3＋,Y^3＋,Gd^3＋;Glu=L-谷氨酸;Im=咪唑）,TEM电镜测试表明其有一定规则形貌,粒径在30-60 nm。通过抗菌实验对其抑菌效果进行研究,结果表明：6种纳米稀土三元配合物对大肠杆菌、金黄色葡萄球菌和白色念珠菌均有较强的抑制作用（最小抑菌浓度MIC分别约为140,100,250μg·ml^-1）,属于广谱抗菌剂;抗菌效果明显优于非纳米稀土三元配合物、稀土氯化物、L-谷氨酸或咪唑。     

砷配合物的固相合成、表征及抑菌活性研究

一些砷、锑的配合物具有抗癌、杀菌等生物功能[1,2],可用于药物研究.近年来,用砷剂(主要是三氧化二砷)治疗急性早幼粒细胞白血病(APL),具有缓解率高而复发率低的优点,引起世人的关注.因砒霜中仅含氧和砷,起药物作用的实际是砷(Ⅲ).因此,选择有生物功能的配体合成新型砷配合物对治疗白血病可能有一定药物作用.由于砷的无机盐易水解,故合成砷的生物配合物很困难,对砷配合物的研究也很少报道 [3-7].本文用异烟肼、L-苯丙氨酸和三碘化砷通过室温固相反应合成了两种未见报道的砷配合物,经元素分析,紫外光谱,X-射线粉末衍射,中、远红外光谱和热重差热分析确定了配合物的化学组成,并对配合物的抑菌活性进行了研究.     

Novel polycationic biocides: Synthesis and antibacterial activity of polymeric phosphonium salts

Various polymeric phosphonium salts and the corresponding low-molecular-weight model compounds were prepared and their antibacterial activities against Staphylococcus aureus and Escherichia coli were explored by the viable cell counting method in sterile distilled water. Antibacterial activity of the polymers was found to be higher than that of the corresponding model compounds, particularly against S. aureus. Furthermore, the polymeric phosphonium salt exhibited a higher activity by 2 orders of magnitude than the polymeric quaternary ammonium salt with the same structure except the cationic part. Compounds with the longest alkyl chain (octyl) studied were found to exhibit particularly high activity, and this finding may be ascribed to the contribution of the increased hydrophobicity of the compounds to the cidal activity. © 1993 John Wiley & Sons, Inc.